Teva Pharmaceuticals, MedinCell get UZEDY FDA approval for schizophrenia
Teva Pharmaceuticals and MedinCell have bagged approval for UZEDY (risperidone) extended-release injectable suspension from the US Food and Drug Administration (FDA) for schizophrenia treatment in adults. UZEDY is a subcutaneous, long-acting formulation of risperidone that uses MedinCell’s copolymer technology SteadyTeq that regulates the fixed release of risperidone. Therapeutic blood concentrations are achieved within six to […]